BELLUS Health (BLU) Stock Price, News & Analysis

Company Overview

BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada. As of June 28, 2023, BELLUS Health Inc. operates as a subsidiary of GSK plc.

Key Stats

• Today's Range: $14.74 to $14.75
• 50-Day Range: $14.42 to $14.75
• 52-Week Range: $6.38 to $14.76
• Volume: 3.45 million shs
• Average Volume: 3.08 million shs
• Market Capitalization: $1.87 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BLU Stock Analysis - Frequently Asked Questions

How were BELLUS Health's earnings last quarter?

BELLUS Health Inc. (NASDAQ:BLU) released its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.29) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by $0.07. BELLUS Health had a negative trailing twelve-month return on equity of 24.27% and a negative net margin of 578,586.63%.

What other stocks do shareholders of BELLUS Health own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BELLUS Health investors own include NIO (NIO), Meta Platforms (META), Pfizer (PFE), Sorrento Therapeutics (SRNE), Alibaba Group (BABA), Tesla (TSLA) and Ford Motor (F).

Company Calendar

• Last Earnings: 11/10/2021
• Today: 6/22/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: NASDAQ:BLU
• CIK: 1259942
• Web: www.bellushealth.com
• Phone: (450) 680-4500
• Fax: 45-0680-4501
• Employees: 74
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.72)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$76.08 million
• Net Margins: -578,586.63%
• Pretax Margin: -578,226.56%
• Return on Equity: -24.27%
• Return on Assets: -23.14%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 33.42
• Quick Ratio: 33.42

Sales & Book Value

• Annual Sales: $15 thousand
• Price / Sales: 124,613.93
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.09 per share
• Price / Book: 4.77

Miscellaneous

• Outstanding Shares: 126,812,000
• Free Float: 96,162,000
• Market Cap: $1.87 billion
• Optionable: Not Optionable
• Beta: 0.19